JP6963509B2 - 自己免疫障害及び同種免疫障害の処置方法 - Google Patents

自己免疫障害及び同種免疫障害の処置方法 Download PDF

Info

Publication number
JP6963509B2
JP6963509B2 JP2017567174A JP2017567174A JP6963509B2 JP 6963509 B2 JP6963509 B2 JP 6963509B2 JP 2017567174 A JP2017567174 A JP 2017567174A JP 2017567174 A JP2017567174 A JP 2017567174A JP 6963509 B2 JP6963509 B2 JP 6963509B2
Authority
JP
Japan
Prior art keywords
antibody
seq
cdr
amino acid
cdrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017567174A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526330A5 (enExample
JP2018526330A (ja
Inventor
グラハム パリー，
パベル エー． ニキーチン，
サンディップ パニカー，
Original Assignee
バイオベラティブ ユーエスエー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオベラティブ ユーエスエー インコーポレイテッド filed Critical バイオベラティブ ユーエスエー インコーポレイテッド
Publication of JP2018526330A publication Critical patent/JP2018526330A/ja
Publication of JP2018526330A5 publication Critical patent/JP2018526330A5/ja
Application granted granted Critical
Publication of JP6963509B2 publication Critical patent/JP6963509B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017567174A 2015-06-26 2016-06-23 自己免疫障害及び同種免疫障害の処置方法 Active JP6963509B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185362P 2015-06-26 2015-06-26
US62/185,362 2015-06-26
PCT/US2016/039087 WO2016210172A1 (en) 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders

Publications (3)

Publication Number Publication Date
JP2018526330A JP2018526330A (ja) 2018-09-13
JP2018526330A5 JP2018526330A5 (enExample) 2019-07-25
JP6963509B2 true JP6963509B2 (ja) 2021-11-10

Family

ID=57585852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567174A Active JP6963509B2 (ja) 2015-06-26 2016-06-23 自己免疫障害及び同種免疫障害の処置方法

Country Status (12)

Country Link
US (3) US20180169240A1 (enExample)
EP (1) EP3313417A4 (enExample)
JP (1) JP6963509B2 (enExample)
KR (1) KR20180020296A (enExample)
CN (1) CN108348600A (enExample)
AU (2) AU2016282782A1 (enExample)
CA (1) CA2990662A1 (enExample)
EA (1) EA038567B1 (enExample)
HK (1) HK1254030A1 (enExample)
IL (1) IL256424B2 (enExample)
MX (2) MX2017016835A (enExample)
WO (1) WO2016210172A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
US8945562B2 (en) 2012-11-02 2015-02-03 True North Therapeutics, Inc. Anti-complement C1s antibodies
EP3280440B1 (en) 2015-04-06 2022-11-16 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
JP6799076B2 (ja) * 2016-04-29 2020-12-09 ファイザー・インク インターフェロンベータ抗体およびその使用
PE20191031A1 (es) 2016-10-12 2019-08-05 Bioverativ Usa Inc ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS
CN111556895B (zh) 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
US12473353B2 (en) 2019-05-15 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule, a pharmaceutical composition, and a method
WO2021075479A1 (en) * 2019-10-16 2021-04-22 Chugai Seiyaku Kabushiki Kaisha An antibody, a pharmaceutical composition, and a method
IL300376A (en) * 2020-08-06 2023-04-01 Bioverativ Usa Inc Inflammatory cytokines and fatigue in subjects with complement-mediated disease
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013945A1 (en) * 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
AU2003270330B2 (en) * 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
CA2720682A1 (en) * 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
CN104870475B (zh) * 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
US8945562B2 (en) * 2012-11-02 2015-02-03 True North Therapeutics, Inc. Anti-complement C1s antibodies

Also Published As

Publication number Publication date
CA2990662A1 (en) 2016-12-29
IL256424B1 (en) 2024-05-01
IL256424A (en) 2018-02-28
BR112017027578A2 (pt) 2018-08-28
AU2016282782A1 (en) 2018-01-18
MX2017016835A (es) 2018-08-01
EP3313417A4 (en) 2019-06-12
EA201890106A1 (ru) 2018-05-31
CN108348600A (zh) 2018-07-31
WO2016210172A1 (en) 2016-12-29
AU2022215307A1 (en) 2022-09-08
AU2022215307B2 (en) 2025-09-04
HK1254030A1 (zh) 2019-07-12
IL256424B2 (en) 2024-09-01
US20180169240A1 (en) 2018-06-21
US20250295768A1 (en) 2025-09-25
NZ738570A (en) 2025-05-02
KR20180020296A (ko) 2018-02-27
EA038567B1 (ru) 2021-09-15
MX2023002021A (es) 2023-03-15
EP3313417A1 (en) 2018-05-02
US20220249664A1 (en) 2022-08-11
JP2018526330A (ja) 2018-09-13

Similar Documents

Publication Publication Date Title
JP6963509B2 (ja) 自己免疫障害及び同種免疫障害の処置方法
JP6938383B2 (ja) イヌインターロイキン４受容体アルファに対する抗体
JP5782132B2 (ja) 抗ＣＤ４０抗体のサイレントＦｃ変異体
JP6646100B2 (ja) 抗ｃｘｃｒ３抗体
JP7246320B2 (ja) ヒト抗セマフォリン４ｄ抗体
JP2009530290A (ja) Ｃｄ４抗体を使用するループスの治療方法
RU2712251C1 (ru) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
JP2010505447A (ja) 抗ｃｄ２０抗体および使用法
WO2006089141A2 (en) Antibodies against cxcr4 and methods of use thereof
JP2021524839A (ja) 抗ｐｃｓｋ９抗体を含む製剤およびその使用
US20240092926A1 (en) Immunomodulatory antibodies and uses thereof
CN113194996A (zh) 克拉扎珠单抗用于治疗慢性抗体介导的器官移植物排斥反应
CN101443040A (zh) 用cd4抗体治疗狼疮的方法
JP2019508415A (ja) 抗シトルリン化ｈｌａポリペプチド抗体及びその使用
BR122024005916A2 (pt) Uso de um anticorpo que se liga especificamente ao componente 1s (c1s) do complemento no tratamento de distúrbios autoimunes
RU2816994C2 (ru) Антитела к bcma, содержащие только тяжелую цепь
BR112017027578B1 (pt) Método in vitro de monitoramento da eficácia de um método de tratamento que compreende administrar um anticorpo anti-c1s
RU2776443C2 (ru) Антитела человека против семафорина 4d
WO2025051083A1 (zh) 抗bdca-2特异性抗体及其用途
EA046818B1 (ru) Интерферон-ассоциированные антигенсвязывающие белки для лечения инфекции, вызванной вирусом гепатита в
HK40015176A (zh) 抗lilrb3抗体及其使用方法
EA040553B1 (ru) Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210624

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211015

R150 Certificate of patent or registration of utility model

Ref document number: 6963509

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250